2 weeks Ago By Defense World Staff
Atara Biotherapeutics, Inc. ( NASDAQ:ATRA – Get Free Report ) has received a consensus recommendation of “Hold” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company.
The average twelve-month target price among brokers that have issued a report on the stock in the last year is $14.00. A number of brokerages recently weighed in on ATRA.
StockNews.com assumed coverage on Atara Biotherapeutics in a report on Wednesday, June 26th. They set a “hold” rating on the stock.
The Goldman Sachs Group lowered their price target on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a research note on Wednesday, July 17th.
Canaccord Genuity Group reiterated a “buy” rating and issued a $13.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, August 13th. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and lowered their target price for the stock from $25.
00 to $18.00 in a research report on Friday, August 16th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st.
Check Out Our Latest Stock Report on ATRA Atara Biotherapeutics Stock Performance Atara Biotherapeutics ( NASDAQ:ATRA – Get Free Report ) last announced its earnings results on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing the consensus estimate of ($1.
56) by ($1.54). The business had revenue of $28.
64 million during the quarter, compared to the consensus estimate of $48.30 million. As a group, equities analysts expect that Atara Biotherapeutics will post -12.
09 earnings per share for the current year. Institutional Trading of Atara Biotherapeutics Hedge funds have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC purchased a new position in Atara Biotherapeutics during the second quarter worth approximately $79,000.
Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics in the 2nd quarter worth $53,000.
Redmile Group LLC boosted its holdings in Atara Biotherapeutics by 1.7% in the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after acquiring an additional 156,863 shares during the last quarter.
Price T Rowe Associates Inc. MD grew its position in Atara Biotherapeutics by 8,916.3% during the first quarter.
Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after acquiring an additional 4,903,159 shares during the period. Finally, Delap Wealth Advisory LLC acquired a new stake in Atara Biotherapeutics during the first quarter worth about $29,000.
70.90% of the stock is owned by institutional investors and hedge funds. Atara Biotherapeutics Company Profile ( Get Free Report Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. See Also Five stocks we like better than Atara Biotherapeutics Most active stocks: Dollar volume vs share volume CarMax’s Impressive Rally: What Investors Should Watch Next 5 discounted opportunities for dividend growth investors MarketBeat Week in Review – 9/23 – 9/27 Stock Average Calculator Wake Up to This Biotech Stock That Still Has Big Potential Upside Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
